Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 1, 2013, Pages 70-77

  Jensen, Kenneth Højsgaard ^a,b   Hilsted, Linda ^a   Jensen, Claus ^a   Mynster, Tommie ^a,b   Rehfeld, Jens F ^a   Knigge, Ulrich ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carcinoid tumors; Chromogranin A; Computed tomography; Neuroendocrine tumors; Radioimmunoassay; RECIST 1.1; Somatostatin receptors

Indexed keywords

CHROMOGRANIN A;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CECUM TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; ILEUM TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CECAL NEOPLASMS; CHROMOGRANIN A; FEMALE; HUMANS; ILEAL NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84871379143     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.733953     Document Type: Article

References (37)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
2. Oberg K, Jelic S. ESMO Guidelines Working Group Neuroendocrine Gastroenteropancreatic tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:150-3.
3. Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Ann Oncol 2010;49:740-56.
4. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumours. Cancer 2003;97:934-59. (Pubitemid 36173145)
5. Helle KB. Chromogranin A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system. Results Probl Cell Differ 2010;50: 21-44.
6. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours-well-differentiated jejunal-ileal tumour/carcinoma. Neuroendocrinology 2008;87:8-19. (Pubitemid 350308290)
7. Eriksson B, Oberg K, Stridsberg M. Tumour markers in neuroendocrine tumours. Digestion 2000;62(Suppl):33-8.
8. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumours: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90. (Pubitemid 27372168)
9. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study. Endocr Relat Cancer 2007;14:473-82. (Pubitemid 47242645)
10. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, de Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-8. (Pubitemid 27337883)
11. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004;60:644-52. (Pubitemid 38669857)
12. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011;96: 3741-9.
13. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumours. Clin Gastroenterol Hepatol 2008;6: 820-7.
14. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumours. Cancer 1999;86:858-65. (Pubitemid 29399927)
15. Borglum T, Rehfeld JF, Drivsholm LB, Hilsted L. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumours and small-cell lung carcinomas. Clin Chem 2007;53:438-46. (Pubitemid 46447940)
16. Jensen TB, Hilsted L, Rehfeld JF. Library of sequencespecific radioimmunoassays for human chromogranin A. Clin Chem 1999;45:549-60. (Pubitemid 29165966)
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
18. Bosman FT, Carneiro F, Hruban RH, Theise ND. editors. WHO Classification of tumours of the digestive system. Lyon: IARC Press; 2010.
19. Stinner B, Rothmund M. Neuroendocrine tumours (carcinoids) of the appendix. Best Pract Res Clin Gastroenterol 2005;19:729-38. (Pubitemid 41614120)
20. Plockinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: welldifferentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008;87:20-30. (Pubitemid 350308291)
21. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150:299-303. (Pubitemid 38443779)
22. Tramonti G, Ferdeghini M, Annichiarico C, Norpoth M, Donadio C, Bianchi R, et al. Relationship between renal function and blood level of chromogranin A. Ren Fail 2001; 23:449-57. (Pubitemid 32692280)
23. Rindi G, Klöppel G, Couvelard A, Komminoth P, KörnerM, Lopes JM, et al. TNMstaging of midgut and hindgut (neuro) endocrine tumours: A consensus proposal including a grading system. Wirchows Arch 2007;451:757-62. (Pubitemid 47497934)
24. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: Is it a useful marker of neuroendocrine tumours? J Clin Oncol 2007;25:1967-73. (Pubitemid 46972778)
25. Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 1999;85: 1470-83. (Pubitemid 29152818)
26. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177:337-41. (Pubitemid 36656407)
27. Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept 2004;117:219-27. (Pubitemid 38121658)
28. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011;140:444-53.
29. Peracchi M, Conte D, Gebbia C, Penati C, Pizzinelli S, Arosio M, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumours or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003;148:39-43. (Pubitemid 36176003)
30. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12:S69-72. (Pubitemid 33069690)
31. Tomassetti P, Migliori M, Simoni P, De lasio R, Corinaldesi R, Gullo L. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001;13:55-8. (Pubitemid 32099569)
32. Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, et al. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumours: Lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 2006;33:250-4. (Pubitemid 44470140)
33. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumours. Neuroendocrinology 2009;89: 302-7.
34. Abou-Saif A, Gibril F, Ojeaburu JV, Bashir S, Entsuah LK, Asgharian B, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumour burden in patients with gastrinomas. Cancer 2003;98:249-61. (Pubitemid 36828447)
35. Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumours. Ann Surg Oncol 2007; 14:780-5. (Pubitemid 46175327)
36. Sondenaa K, Sen J, Heinle F, Gudlaugsson E, Syversen U. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: Preliminary report. World J Surg 2004;28:890-5. (Pubitemid 39391893)
37. Korse CM, Bonfrer JMG, Aaronson NK, Hart AAM, Tall BG. Chromogranin A as an alternative to 5-Hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumours. Neuroendocrinology 2009;89:296-301.